The
tumor-associated
glycoprotein 72 (TAG-72) is a membrane
mucin whose over-expression is correlated with advanced
tumor stage and increased invasion and
metastasis. In this study, we identified a panel of four
nanobodies, single variable domains of dromedary heavy-chain
antibodies that specifically recognize the
TAG-72 antigen. All selected
nanobodies were shown to selectively bind to this
cancer-related molecule with low-nanomolar affinities and do not cross-react with other
antigens, such as MUC1 or HER2. Furthermore, they can detect
TAG-72 in concentrations as low as 5 U/ml which is valuable in sensitive detection of this molecule in cancerous patients. Cell ELISA experiments proved their ability for binding to the native target
antigen on
TAG-72 expressing cells while not showing any reactivity to HT-29 cells, a TAG-72-negative cell line. Using competition studies, we found that each nanobody recognizes a distinct
epitope on the
TAG-72 antigen that is different from the one recognized by the mouse anti-TAG-72 antibody, CC49. Considering their high specificity, reduced immunogenicity and multi-targeting behavior, these oligoclonal
nanobodies represent a promising tool to target
TAG-72 over-expressing
tumor cells.